title: Administered CpG oligodeoxynucleotide induces mRNA expression of CXC and CC chemokines at the intestinal mucosa and PBMCs in piglets.
abstract: Oligonucleotides containing CpG motifs (CpG ODN) are known to be potent stimulators of the innate immune system in vitro and in vivo. We therefore investigated if intranasal (IN)-mucosal or intramuscular (IM)-systemic administration of CpG ODN could enhance innate immunity in the intestinal mucosa and peripheral blood mononuclear cells (PBMCs) in piglets. Repeated IN or IM administration of CpG ODN significantly increased local/systemic mRNA expression of the CC chemokines macrophage inflammatory protein 1beta (MIP-1beta) and monocyte chemoattractant protein-1 (MCP-1) and CXC chemokine gamma interferon-inducible protein 10 (IP-10) and percentages of macrophages and cDCs in the intestine (jejunum, caecum and colon) and PBMCs by different kinetics. IN delivery of CpG ODN induced much stronger chemokine responses than IM delivery at intestinal mucosas, whereas IN delivery of CpG ODN induced some weaker chemokine responses than IM delivery in PBMCs. These findings suggest that IN administration of 100mug/kg-CpG ODN without antigen codelivery may represent a valuable strategy for induction of innate immunity against infection.
authors.affiliation: College of Life Sciences, South China Agricultural University, Guangzhou 510642, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Cheng
authors.forename: Chenchao
authors.initials: C
authors.lastname: Xu
authors.forename: Linghua
authors.initials: L
authors.lastname: Zhang
authors.forename: Jiaoqing
authors.initials: J
authors.lastname: Li
authors.forename: Ting
authors.initials: T
authors.lastname: Cao
authors.forename: Meirong
authors.initials: M
authors.lastname: Zhang
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D002452:Cell Count; D002465:Cell Movement / Q000187:drug effects; D018932:Chemokine CCL2 / Q000096:biosynthesis* / Q000235:genetics; D054407:Chemokine CCL4 / Q000096:biosynthesis* / Q000235:genetics; D018899:CpG Islands / Q000235:genetics; D003713:Dendritic Cells / Q000473:pathology; D007113:Immunity, Innate; D007273:Injections, Intramuscular; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000235:genetics; D011744:Pyrimidinones / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis*; D013552:Swine; D013844:Thiazoles / Q000378:metabolism; D014611:Vaccination
chemical_list: D018932:Chemokine CCL2; D054407:Chemokine CCL4; D009838:Oligodeoxyribonucleotides; D011744:Pyrimidinones; D012333:RNA, Messenger; D013844:Thiazoles; C041057:5(4'-hydroxybenzylidenoimino)-3-methylisothiazolo(5,4-d)pyrimidine-(7H)-4,6-dione